Xencor, Inc. (NASDAQ:XNCR - Get Free Report)'s share price passed above its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $8.55 and traded as high as $9.48. Xencor shares last traded at $9.28, with a volume of 772,711 shares traded.
Wall Street Analyst Weigh In
Several research firms have recently commented on XNCR. William Blair began coverage on shares of Xencor in a report on Monday, April 21st. They issued an "outperform" rating for the company. Wall Street Zen lowered shares of Xencor from a "hold" rating to a "sell" rating in a report on Friday, March 14th. Barclays decreased their price target on shares of Xencor from $22.00 to $6.00 and set an "underweight" rating for the company in a report on Thursday, May 8th. Finally, Wedbush reaffirmed an "outperform" rating and issued a $31.00 price target on shares of Xencor in a report on Wednesday, April 30th. Two analysts have rated the stock with a sell rating and seven have assigned a buy rating to the company's stock. Based on data from MarketBeat, Xencor currently has a consensus rating of "Moderate Buy" and a consensus target price of $28.00.
Read Our Latest Stock Analysis on Xencor
Xencor Stock Performance
The stock has a market capitalization of $628.43 million, a P/E ratio of -2.89 and a beta of 0.85. The company's 50-day moving average is $8.50 and its two-hundred day moving average is $12.89. The company has a current ratio of 5.89, a quick ratio of 5.89 and a debt-to-equity ratio of 0.16.
Xencor (NASDAQ:XNCR - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($0.66) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.06). The firm had revenue of $32.73 million during the quarter, compared to the consensus estimate of $23.44 million. Xencor had a negative net margin of 181.17% and a negative return on equity of 31.94%. The company's revenue for the quarter was up 104.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($1.11) earnings per share. As a group, sell-side analysts anticipate that Xencor, Inc. will post -3.68 EPS for the current fiscal year.
Insider Activity
In other news, Director Richard J. Ranieri sold 2,993 shares of the company's stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $9.22, for a total value of $27,595.46. Following the completion of the sale, the director directly owned 19,183 shares of the company's stock, valued at approximately $176,867.26. This represents a 13.50% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Kurt A. Gustafson sold 2,993 shares of the company's stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $9.22, for a total transaction of $27,595.46. Following the completion of the sale, the director directly owned 20,183 shares of the company's stock, valued at approximately $186,087.26. This represents a 12.91% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 15,810 shares of company stock valued at $154,123. 4.76% of the stock is owned by company insiders.
Institutional Trading of Xencor
A number of institutional investors have recently made changes to their positions in XNCR. Sterling Capital Management LLC increased its position in shares of Xencor by 732.4% in the fourth quarter. Sterling Capital Management LLC now owns 1,182 shares of the biopharmaceutical company's stock worth $27,000 after acquiring an additional 1,040 shares in the last quarter. GF Fund Management CO. LTD. acquired a new stake in shares of Xencor during the fourth quarter worth approximately $34,000. State of Wyoming acquired a new stake in shares of Xencor during the first quarter worth approximately $34,000. CWM LLC boosted its holdings in shares of Xencor by 195.5% during the first quarter. CWM LLC now owns 3,372 shares of the biopharmaceutical company's stock worth $36,000 after purchasing an additional 2,231 shares during the period. Finally, PNC Financial Services Group Inc. boosted its holdings in shares of Xencor by 49.4% during the fourth quarter. PNC Financial Services Group Inc. now owns 4,041 shares of the biopharmaceutical company's stock worth $93,000 after purchasing an additional 1,337 shares during the period.
Xencor Company Profile
(
Get Free Report)
Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.
Further Reading
Before you consider Xencor, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xencor wasn't on the list.
While Xencor currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
